SYCAMORENCT05085561
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 19 versions: 16 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Results posted: Oct 22, 2026
- Eligibility criteria expanded, about 14 words
- Primary endpoint revised
- Secondary endpoints: 5 to 8
Notable Primary endpoints: 2 to 1v17 Show 4 more changesShow less
- Trial status: Active, Not Recruiting to Completed
- Primary and study completion dates changed from estimate of Dec 2025 to Jun 30, 2025
- Secondary endpoints: 6 to 5
- Study description expanded, about 32 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 60 to confirmed 62
- Site details revised at 15 of 15 sites
Notable Primary and study completion dates: Jun 2024 to Dec 2025v14 Show 4 more changesShow less
- Eligibility criteria expanded, about 20 words
- Primary endpoints revised (2)
- Study sites: 13 to 15
- Secondary endpoints expanded, about 54 words
- Minor Study sites: 12 to 13v13
Show 10 earlier versionsHide 10 earlier versions
- Minor Site contacts updated at 9 of 12 sitesv12
- Minor Study sites: 11 to 12v11
- Minor Site details revised at 2 of 11 sitesv10
- Minor Site details revised at 1 of 11 sitesv9
- Minor Site details revised at 1 of 11 sitesv8
- Minor Site details revised at 1 of 11 sitesv7
- Minor Study sites revised (11)v6
- Minor Study sites: 7 to 11v5
- Notable Eligibility criteria shortened, about 1 word
- Start date changed from estimate of Mar 2022 to Mar 17, 2022
- Site details revised at 1 of 7 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Dec 1, 2021 to Mar 2022
- Study sites: 0 to 7
- Primary and study completion dates: Jun 1, 2024 to Jun 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Timeframe: Up to a maximum of 1201 days
Secondary (8)
Part 1: Change From Baseline in Modified Rankin Scale (mRS) Score at Month 12
Part 1: Change From Baseline in Total SymptoMScreen (SMSS) Score at Month 12
Part 1: Change From Baseline in Cerebral Cavernous Malformation Health Index (CCM-HI) Total Score at Month 12
Part 1: Clinical Global Impressions - Improvement (CGI-I) Scale Score at Month 12
Part 1: Patient Global Impressions - Improvement (PGI-I) Scale Score at Month 12
Show 3 moreShow less
Part 1: Change From Baseline in Number of Monthly Seizures at Month 12
Part 1: Change From Baseline in Number of Monthly Headaches at Month 12
Number of Participants With Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) Confirmed Cerebral Haemorrhagic Events
Arms and interventions
REC-994 200 mgExperimental
Participants received REC-994 200 milligrams (mg) orally once daily (QD) (1 200 mg REC-994 tablet, 1 matching placebo tablet)
REC-994 400 mgExperimental
Participants received REC-994 400 mg orally QD (2 200 mg REC-994 tablets)
PlaceboPlacebo comparator
Participants received matching placebo orally QD (2 matching placebo tablets)
Drugs: REC-994, Placebo
Sites
15 sites in 1 country